Le site du Docteur Mario OJEDA URIBE

Hématologie

Autres

  • Liste de publications

      BIBLIOGRAPHY List of publications and citations Including links can be found at Pubmed or Google Scholar: search for Ojeda-Uribe M, Ojeda Uribe M, Ojeda Uribe, Ojeda M, Uribe MO 3.1 Peer-reviewed Articles 1. Tang R, Beuvon F, Ojeda M, Mosseri V, Pouillart P. M-CSF (monocyte colony stimulating factor) and M-CSF receptor expressing by breast tumor cells. M-CSF mediated recruitment of tumor infiltrating lymphocytes? J Cell Biochem 1992 Dec;50(4):350-56 2. Ojeda M. Limiting dilution analysis and characterization of spindle-shaped fibroblastoid CFC in bone marrow and peripheral blood. Int J Cell Cloning 1992; 10 (suppl 1):9-11. 3. Ojeda Uribe M, Brunot A, Lenat A, Legros M. Failure to detect spindle-shaped fibroblastoid cell progenitors in PBPC collections. Acta Haematologica 1993;90:139-43 4. P Moreau, J Fleury, P Brice, P Colombat, R Rouabdallah, B Lioure, L Voilat, O Casasnovas, S François, A Sadoun, T Lamy, JP Lotz, JN Munck, M Divine, C Fermé, AM Peny, C Fruchart, P Oriol, M Ojeda, O Reman, N Milpied, C Gisselbrecht, M Legros, JL Harousseau. Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease:retrospective analysis of 158 cases from the French registry. Bone Marrow Transplantation 1998;21: 787-793 5. Henon Ph, Sovalat H, Becker M, Arkam Y, Ojeda-Uribe M, Raidot JP, Husseini F, Wunder E, Bourderont D, Audhuy B. Primordial role of CD34+38- cells in early and late trilineage hematopoietic engraftment after autologous blood cell transplantation. British Journal of Haematology 1998;103:568-581 6. Henon Ph, Sovalat H, Bourderont D, Ojeda-Uribe M, Arkam Y, Wunder E, Raidot JP, Husseini F, Audhuy B. Role of CD34+38- cells in posttransplant hematopoietic recovery. Stem Cells 1998;16(1): 113-122 7. H Sovalat, E Racadot, M Ojeda, H Lewandowski, V Chabouté , Ph Henon. CD34+ cells and CD34+38- subset from mobilized blood show different patterns of adhesion molecules compared to those from steady-state blood, bone marrow and cord blood. Journal of Hematotherapy and Stem Cell Research 2003;12:473-489 8. Ojeda-Uribe M, Sovalat H, Bourderont D, Brunot A, Marr A, H Lewandowski, V Chabouté, Peter P, Henon Ph. Peripheral blood and bone marrow CD34+38- cells show better resistance to cryopreservation than CD34+38- cells in autologous stem cell transplantation. Cytotherapy 2004; 6(6) : 571-583 9. M Ojeda-Uribe, A Brunot, M Issler. Successful treatment of idiopathic acquired refractory thombotic thrombocytopenic Purpura with an association Rituximab-Vindesine. Rev Med Chil 2005; 133:1349-1354. 10. D Rea D, L Legros, E Raffoux, X Thomas, P Turlure, S Maury, B Dupriez, A Pigneux, B Choufi, O Reman, D Stéphane, B Royer, M Vigier, M Ojeda-Uribe, C Recher, H Dombret, F Huguet, P Rousselot. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukaemia and lymphoid blast crisis of chronic myeloid leukaemia. Leukemia 2006; 20:400-403 11. Ojeda-Uribe M, Gilliot C Jung G, Drenou B, Brunot A. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. Journal of Perinatology 2006;26: 252-55 12. Imperiale A, Blondet C, Ben-Sellem D, Forestier E, Mohseni M, Piemont Y, Ojeda M, Christmann D, Constantinesco A, Hansmann Y. Unusual abdominal localisation of cat scratch disease mimicking malignancy on F-18 FDG PET/CT examination. Clin Nucl Med. 2008; 33(9):621-3 13. L Oberic, M Buffet, M Schwarzinger, A Veyradier, K Clabault, S Malot, N Schleinitz, D Valla, L Galicier, L Bengrine-Lefèvre, NC Gorin, P Coppo, for the Reference Center for the Management of Thrombotic Microangiopathies : Azoulay E, Bordessoule D, Brivet F, Buffet M, Bussel A, Coppo P, Charasse C, Choukroun G, Clabault K, Daubin C, Deschenes G, Devidas A, Fain O, Fremeaux-Bacchi V, Galicier L, Guidet B, Gruson D, Herbrecht R, Ifrah N, Korach JM, Malot S, Loirat C, Mira JP, Monge M, Moulin B, Mousson C, Nivet H, Ojeda Uribe M, Ouchenir A, Palcoux JB, Poullin P, Pourrat J, Pouteil-Noble C, Provot F, Ramakers M, Regnier B, Ribeil JA, Rondeau E, Schlemmer B, Leblanc T, Vernant JP, Veyradier A, Vigneau C, Vincent F, Vrtovsnick F, Wynckel A, Wolf M, Zunic P. Cancer Awareness in Atypical Thrombotic Microangiopathies . The Oncologist 2009;14(8): 769-79. 14. S Pasquet, H Sovalat, Ph Henon, N Bischoff, Y Arkam, M Ojeda Uribe, R Le Bouar, V Rimelen, I Brink, R Dallemand, JP Monassier. Long-term benefit of Intracardiac delivery of autologous granulocyte-colony-stimulating-factor-mobilized blood CD34+ cells containing cardiac progenitors on regional heart structure and function after myocardial infarct . Cytotherapy 2009;11:1002-1015 15. M Ojeda-Uribe, L Federici, M Wolf, P Coppo, A Veyradier. Successful long-term Rituximab maintenance for a relapsing patient with idiopathic thrombotic thrombocytopenic purpura. Transfusion 2010; 50: 753-756 16. L Federici, M Ojeda-Uribe. Microangiopathies Thrombotiques: aspects physiopathologiques, diagnostiques, thérapeutiques et pronostiques. Médecine Thérapeutique, 2010; 16: 47-54 17. Coppo P, Busson M, Veyradier A, Wynckel A, Poullin P, Azoulay E, Galicier L, Loiseau P; French Reference Centre For Thrombotic Microangiopathies Bordessoule D, Brivet F, Buffet M, Bussel A, Charasse C, Choukroun G, Clabault K, Daubin C, Devidas A, Fain O, Frémeaux-Bacchi V, Guidet B, Gruson D, Hamidou M, Heshmati F, Ifrah N, Korach JM, Le Guern V, Malot S, Mira PJ, Monge M, Moulin B, Mousson C, Nivet H, Ojeda-Uribe M, Ouchenir A, Palcoux JB, Pourrat J, Pouteil-Noble C, Provôt F, Ramakers M, Regnier B, Ribeil JA, Rondeau E, Schlemmer B, Leblanc T, Vernant JP, Vigneau C, Vincent F, Wolf M, Zunic. HLA-DRB1*11: a strong risk factor for acquired severe ADAMTS13 deficiency-related idiopathic thrombotic thrombocytopenic purpura in Caucasians. J Thromb Haemost. 2010 Apr;8(4):856-9. 18. M Ojeda-Uribe, C Caron, N Itzhar-Baikian, A Debliquis. Bortezomib effectiveness in one patient with acquired von Willebrand Syndrome associated to monoclonal gammopathy of undetermined significance. American Journal of Hematology, 2010;85: 396 19. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, et al. French Reference Centre For Thrombotic Microangiopathies Bordessoule D, Brivet F, Buffet M, Bussel A, Charasse C, Choukroun G, Clabault K, Daubin C, Devidas A, Fain O, Frémeaux-Bacchi V, Guidet B, Gruson D, Hamidou M, Heshmati F, Ifrah N, Korach JM, Le Guern V, Malot S, Mira PJ, Monge M, Moulin B, Mousson C, Nivet H, Ojeda-Uribe M, Ouchenir A, Palcoux JB, Pourrat J, Pouteil-Noble C, Provôt F, Ramakers M, Regnier B, Ribeil JA, Rondeau E, Schlemmer B, Leblanc T, Vernant JP, Vigneau C, Vincent F, Wolf M, Zunic (2010) Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience. PLoS ONE 2010 ;5 : 5(4): e10208(1-9) 20. M Ojeda-Uribe, R Herbrecht, Ph Schultz, MH Kiefer, J Chain, MP Chenard, JM Servant, C Debry. Lessons from a case of oro-mandibular mucormycosis treated with surgery and a combination of Amphotericine B lipid formulation plus Caspofungin. Acta Haematologica 2010; 124:98-102 21. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet F, Maloisel F, Coiteux V, Gardembas M, Berthou C, Vekhoff A, Rea D, Jourdan E, Allard C, Delmer A, Rousselot P, Legros L, Berger M, Corm S, Etienne G, Roche-Lestienne C, Eclache V, Mahon FX, Guilhot F; SPIRIT Investigators; France Intergroupe des Leucémies Myéloïdes Chroniques (Fi-LMC) : Roy L, Fleck E, Saulnier PJ, Marit G, Bouabdallah K, Leguay T, Schmitt A, Giovanelli HB, Kiladjian JJ, Facon T, Jouet JP, Noel MP, Ifrah N, Dib M, François S, Ame S, Lioure B, Fohrer C, Attal M, Laurent G, Recher C, Nouvel C, Huynch A, Tulliez M, Pautas-Chambon C, Kuentz M, Giraudier S, Maury S, Cordonnier C, Dubruille V, Harousseau JL, Chevallier P, Mahe B, Moreau P, Guillerm G, Dalbies F, Varet B, Buzyn A, Aouba A, Michallet M, Thomas X, Troncy J, Renaudier P, Christian B, Dorvaux V, Visanica S, Guibaud I, Cassuto JP, Karsenti JM, Gorin NC, Coppo P, Rio B, Marie JP, Legrand O, Casassus P, Fenaux P, Goldschmidt E, Bouscary D, Park S, Caillot D, Casasnovas RO, Ahwij N, Ferrant E, Lafon I, Banos A, Bauduer F, Araujo C, Larosa F, Deconinck E, Brion A, Escoffre-Barbe M, Lamy T, Dauriac C, Bernard M, Houot R, Delain M, Colombat P, Gyan E, Lenain P, Contentin N, Stamatouillas A, Leprêtre S, Schoenwald M, Alexis M, Souleau B, De Revel T, Dine G, Ammar NA, Brahimi S, Glaisner S, Janvier M, Cony-Makhoul P, Corront B, Abarah W, Frayer J, Mahfouz I, Simon M, Pollet JP, Fernandes J, Villemagne B, Maisonneuve H, Chatellier T, Priou F, Tiab M, Bonnevie F, Pignon JM, Zerazhi H, Lepeu G, Boulat O, Azzedine A, Slama B, Turlure P, Bordessoule D, Jaccard A, Remenieras L, Touati M, Moreau S, Chaury MP, Girault S, Ojeda-Uribe M, Eisenmann JC, Arkam Y, Drenou B, Blanc M, Besson C, Raphael M, Tertian G, Courby S, Bulabois CE, Gressin R, Richard B, Lavabre bertrand T, Castaigne S, Taksin AL, Fahrat H, Sohn C, Fezoui H, de Jaureguiberry JP, Gisserot O, Jardel H, Godmer P, Dutel JL, Ghomari K, Charbonnier A, Blaise D, Bouabdallah R, Vey N, Aurran-Schleinitz T, Prebet T, Vernant JP, Tona A, Choufi B, Pollet B, Reman O, Leporrier M, Macro M, Cheze S, Launay V, Jonhson-ansah H, Audhuy B, Himberlin C, Kolb B, Thyss A, Peyrade F, Plantier I, Fawaz A, Rossi JF, Quittet P, Fegueux N, Cellabos P, Navarro R, Autrand C, Morel P, Stalnikiewicz L, Dupriez B, Desablens B, Royer B, Damaj GL, Garidi R, Rodon P, Boulet JM, Berger M, Tournilhac O, Chaleteix C, DeRenzis B, Bay O, Hermet E, Aljassem-Abdelkader L, Maigre M, Etienne G, Reiffers J, Eghbali H, Joly B, Devidas A, Bouledroua S, Petitdidier C, Salanoubat C, Fouillard L, Benramdane R, Gonzales H, Vanhaeke D, Guyotat D, Mounier C, Jaubert J, Levaltier X, Giraudeau B, Salles G, Solal-Celigny P. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010 Dec 23; 363(26):2511-21. 22. Perrot A, Luquet A, Mugneret F, Delaunay J, Harousseau JL, Cahn JY, Guardiola Ph, Himberlin C, Recher C, Vey N, Lioure B, Ojeda-Uribe M, Fegueux N, Berthou C, Randriamalala E, Béné MC, Ifrah N, Witz F. Dismal prognostic value of monosomal karyotype (MK) in elderly patients with acute myeloid leukemia (AML): Goelams study of 186 patients with unfavorable cytogenetics abnormalities. Blood. 2011; 118:679-685. 23. R Houot, S Le Gouill, M Ojeda-Uribe, C Mounier, S Courby, C Dartigeas, K Bouabdallah, M Alexis Vigier, MP Moles, O Tournihlac, M Arakelian, Ph Rodon, A El Yamani, L Sutton, B Lioure, D Assouline, JL Harousseau, H Maisonneuve, S Caulet-Maugendre, R Gressin. Phase II study of Rituximab, Bortezomib, Adriblastine, Dexamethasone and Chrolorambucil (RIPAD+C) as first line therapy for elderly mantle cell lymphoma patients. Annals of Oncology 2011 oct 19 (Epub ahead of print) 24. A Berceanu, S Leprêtre, M Ojeda-Uribe, E de Berranger, E d’Incan Corda, D Caillot, E Raffoux, P Ribaud, A Thiebaut, N Milpied, M Michallet, C Cordonnier, R Herbrecht. Prophylaxie antibacterienne et antifongique chez les patients à haut risque en Hématologie. Enquête de pratique et forum. Hématologie 2011; 17 (suppl 4) :3-15 25. B Lioure, MC Béné, A Pigneux, C Recher, P Chevalier, N Fegueux, D Blaise, B Witz, M Delain, J Cornillon, I Luquet, O Blanchet, P Cornillet-Lefebvre, M Carré, M Hunault, F Larosa, T Lamy, E Randriamalala, M Ojeda-Uribe, C Berthou, L Fornecker, JL Harousseau, D Bouscary, N Ifrah, and JY Cahn. Early matched sibling hematopoietic-cell transplantation for adult AML in first remission using an age-adapted strategy: a prospective GOELAMS study. Blood. 2012;119:2943-8 26. Moulin V, Ungureanu C, Ojeda-Uribe M, Thiebault S, Porot C, Angoue O, Boulahdour H. Hematopoïese Extramedullaire Intrathoracique: Intérêt de l’Imagerie Hybride. Journal de Radiologie diagnostique et Interventionnelle, 2012, in press) 27. M Ojeda-Uribe, A Schneider, I Luquet, A Berceanu, P Cornillet-Lefebvre, E Jeandidier, B Lioure, L Ades, L Mauvieux, C Himberlin. Therapy related acute myeloid leukemia (t-AML) with poor-prognosis cytogenetics in two patients with persistent molecular complete remission of acute promyelocytic leukemia ((Eur J Haematol. 2012 May 17. doi: 10.1111/j.1600-0609.2012.01805.x. [Epub ahead of print]) 28. M Ojeda-Uribe, N Afif, E Dahan, L Sparsa, C Haby, D Ternant, M Ardizzone. Exposure to abatacept or rituximab in the first trimester of pregnancy in women with auto-immune diseases (submitted) 29. J Delaunay, C Recher, A Pigneux, F Witz, N Vey, O Blanchet, P Lefebvre, I Luquet, G Guillerme, C Volteau, E Gyan, B Lioure, E Jourdan, D Bouscary, R Guieze, E Randriamalala, M Ojeda-Uribe, F Dreyfus, C Lacombe, MC Béné, JY Cahn, JL Harousseau and N Ifrah. Gemtuzumab Ozogamycin (GO) combined with standard chemotherapy increases antileukemic activity for adults’ AML patients with intermediate cytogenetics. Results of the GOELAMS AML 2006 IR Study. (submitted to JCO) 3.2 CHAPTERS / THESIS 1. Ojeda M. Veno-occlusive disease in bone marrow transplants. Memory as Foreign Assistant in Hematology. University of Paris VI, Paris, France 1989. 2. Henon P, Sovalat H, Becker M, Arkam Y, Ojeda M, Bourderont D. Role of CD34+38- cells in post-transplant hematopoietic recovery. Autologous Bone Marrow Transplantation: Proceedings of the 8th Int. Symposium on ABMT, Arlington. Karel Dicke, Armand Keating (Eds). Carden-Jennings Publishing Co. Ltd, Charlotesville, USA 1997, pp 425-436 3. Ojeda-Uribe M. Mémoire Diplôme d’Université Micro-informatique Bureautique, Université d’Haute Alsace : « Stem Cells and Cell Therapy: Setting up a database for cell therapy in ACCESS ® 2000" (2003) 3.3 Peer-Reviewed Abstracts of Meetings Presentations: oral (Oral-P), poster (P) 1. Ojeda M, Beuvon F, Tang RP, Pouillart P. Macrophage phenotype of breast cancer cells : signal for an invasive phenotype ?. J Cell Biochem 1991; suppl 15B:242 (Growth Factor Transduction Meeting. Steamboat-Springs, U.S.A., 1991) (P) 2. Zhou D, Ojeda M. Iterative studies of mdr1 gene expression in acute myeloid leukemias. Eur J Cancer 1991;27(suppl 2):S247 (EORTC Leukemia Meeting, Rome, 1991) (P) 3. Brunot-Ojeda A, Vidal M, Viallard JL, Marques-Verdier A, Ojeda M, Bonhomme J, Subtil E. Comparative study of buffy-coat platelet concentrates stored in an artificial salt solution and in human plasma. Rev. Paulista de Med.1992; 110(5):SP07. (Congress International Society of Blood Transfusion, Sao Paulo, Bresil) (Oral-P) 4. Faradji A, Bohbot A, Sosa C, Lioure B, Karcher V, Schmitt M, Maloisel F, Herbrecht R, Falkendrodt A, Ojeda M, Audhuy B, Bergerat JP, Oberling F. Collection and PSC Autografting: L’ expérience de Strasbourg. Annales de Médecine Interne 1994 (suppl 1);145:29 (P) 5. Henon Ph, Sovalat H, Becker M, Arkam Y, Ojeda M, Bourderont D. Assessment of the CD34+38- content in autologous blood graft products as predictive factor of post-transplant trilineage engraftment. Exp. Hematology 1996; 24(9): 1049 . (Meeting International Society of Experimental Hematology 1996, New York, U.S.A.) (Oral-P) 6. Lioure B, Moreau P, Witz F, Vilque JP, François S, Brion A, Delain M, Casassus P, Ojeda M, Cahn JY, Oberling F, Harousseau JL. New association of high dose mitoxantrone (Mtx), carboplatin (CBCDA) and VP16 for relapsed or refractory acute myelogenous leukaemia (AML). Blood 1996;88(10) Suppl 1:215a (ASH Annual Meeting Abstracts) (P) 7. Henon P, Sovalat H, Bourderont D, Arkam Y, Ojeda-Uribe M. Both, earliest and latest 3-lineage engraftment are strongly dependent for CD34+38- cells reinfused for autologous blood stem cell transplantation. Blood 1997;90(10) Suppl1:241a (ASH Annual Meeting Abstracts) (P) 8. Henon Ph, Sovalat H, Arkam Y, Ojeda M, Wunder E, Bourderont D. Role of CD34+38- cells in trilineage engraftment following autologous blood cell transplantation. Acta Haematologica 1997;98(suppl 1):2a (10th Symposium on Molecular Biology of Hematopoiesis, Hambourg, Germany, 1997) (Oral-P) 9. Cazin B, Wetterwald M, Ojeda M, Mahé B, Bauters F. Campath 1H in the treatment of T-prolymphocytic leukaemia. Blood 1999 (94) Suppl 1: 125a (ASH Annual Meeting Abstracts) (P) 10. Ojeda-Uribe M, Sovalat H, Bourderont D, Arkam Y, Brunot A, Jeandidier E, Henon Ph. CD34+38- cells show better resistance to cryopreservation than CD34+38+ ones. Blood 1999 (94) Suppl1: 553a (ASH Annual Meeting Abstracts) (P) 11. Cazin B, Wetterwald M, Ojeda M, Mahé B, Bauters F. Campath 1H in the treatment of T-prolymphocytic leukaemia. Hematology and Cell Therapy 2000;42(1):108 . VIII (International Workshop on Chronic Lymphocytic Leukemia, Paris, France, 1999.) (Oral-P) 12. Sovalat H, Ojeda M, Arkam Y, Lewandowsky H, Chabouté V, Henon Ph. Effect of cryopreservation on adhesion molecule expression in peripheral blood derived CD34+ cells. 29th Annual Meeting International Society of Experimental Hematology, Tampa, USA, 2000 (P) 13. Witz F, Harousseau JL, Sadoun A, Cahn JY, Le Prise PY, Tournilihac O, Desablens B, Guyotat D, Vilque JP, Berthou C, Solary E, Ojeda M, Casassus P, François S, Delain M, Dorvaux V, Raby P, Guibon O, Berthaud P, Lioure B. A randomised study of Fludarabine in part of induction and post-remission treatment for de novo acute myeloid leukaemia (AML) in elderly patients. Blood 2000(96) Suppl 1:504a (ASH Annual Meeting Abstracts) (Oral-P) 14. Sovalat H, Ojeda M, Arkam Y, Lewandowsky H, Chabouté V, Henon Ph. Differences in cellular adhesion molecule expression by circulating and bone marrow based CD34+ hematopoietic progenitors after chemotherapy and G-CSF treatment. Acta Hematologica 2000;103 (suppl 1):20 (13th International Symposium Molecular Biology of Hematopoiesis, New-York, USA, 2000.) (Oral-P) 15. Henon Ph, Ojeda-Uribe M, Arkam Y, Bourderont D, H Sovalat. G-CSF administration after autologous peripheral blood stem cell transplantation (PBSCT). Yes or no?. Experimental Hematology 2002;30(6), Suppl 1: 136.( 31th Annual Meeting International Society of Experimental Hematology, Montreal, Canada, 2002.) (Oral-P) 16. Bauduer F, Pelletier X, Leporrier M, Cazin B, Cahn JY, Ojeda-Uribe M, Sirito A, Magnette J, Binet JL. Chlorambucil plus Theophylline (CLB+Theo) versus Chlorambucil (CLB) alone in CLL : a preliminary randomised study. The Hematology Journal 2003(4), Suppl 2: 190 (8th Annual Congress of the European Hematology Association, Lyon, France, juin 2000) (P) 17. H Sovalat, M Ojeda, H Lewandowski, V Chabouté, Ph Henon. Differential expression of adhesion molecules by CD34+ cells from mobilized peripheral blood, bone marrow and cord blood. Journal of Biological Regulators and Homeostatic Agents 2002 (suppl 1):309 (Second Euroconference on Clinical Cytometry: From Pathogenesis to Therapy, Urbino, Italie, septembre 2002.) (Oral-P) 18. H Sovalat, M Ojeda, H Lewandowski, A Kapsa, PRG Henon. Expression of cell adhesion molecules on cord blood and bone marrow hematopoietic progenitors. Acta Angiologica 2003; 9:32a (P) 19. Philippe Henon, Mario Ojeda, Yazid Arkam, Hanna Sovalat, Nicolas Bischoff, Jean-Pierre Monassier, Ingo Brink. Intra-cardiac reinjection of purified autologous blood CD34+ cells mobilized by G-CSF can significantly improve myocardial function in cardiac patients. Blood 2003;102(11): 335a (ASH Annual Meeting Abstracts) (P) 20. Ph Henon, M Ojeda, Y Arkam, H Sovalat, N Bischoff, JP Monassier, I Brink. From blood to heart: autologous blood stem cell transplantation for myocardial regeneration. Acta Angiologica 2003;9 (suppl): 27 (P) 21. Georges Jung, Sylvie Thiebault, Jean-Claude Eisenmann, Eckart Wunder, Marie Haas, Yazid Arkam, Mario Ojeda-Uribe, Philippe Henon. Quantitative phenotyping and discriminant analysis improve scoring classification in late B lymphoproliferative disorders.(abstract 1463). Blood 2005;106 (11): abst. 1463 (ASH Annual Meeting Abstracts) (P) 22. B Lioure, J Delaunoy, D Blaise, N Milpied, P Guardiola, JY Cahn, B Witz, E Jourdan, L Legros, E Randriamalala, M Ojeda, C Himberlin, M Attal. Allogeneic stem cell transplantation (SCT) with non myeloablative conditioning regimen (NST) following intensive consolidation may be equivalent to conventional alloSCT and superior to autoSCT for patients over 50 with acute myeloid leukaemia (AML) in first CR: First results of the AML 2001 Trial. Blood 2006;108(11) :319 (ASH Annual Meeting Abstracts) (Oral-P) 23. F Huguet, F Garban, L Legros, P Turlure, N Fegueux, M Ojeda-Uribe, C Himberlin, P Rousselot, F Witz, O Tournilhac, M Lafage, H Dombret. Une approche pédiatrique des LAL Philadelphie-negatives de l’adulte : resultats du protocole GRAALL 03. Hematologie 2007 ;13(suppl 2) :97 (Congrès Société Française d’Hématologie, Paris, France, 2007) (Oral-P) 24. Remy Gressin, Sylvie Caulet Maugendre, Stevel Le Gouill, Mario Ojeda Uribe, Magda Alexis Vigier, Krimo Bouabdallah, Christine Mounier, Olivier Tournilhac, Philippe Rodon, Abderrazak El Yamani, Laurnt Sutton, Delphine Senecal, Bruno Lioure, David Assouline, Annie Le Mevel, Bruno Villemagne, Charles Dauriac, Martine Gardembas, Sophie Park, Thierry Lamy. Interim results of the Ripad+C regimen including Velcade in front line therapy for elderly patients with mantle cell lymphoma. A Phase II prospective study of the Goelams Group. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1575 (P) 25. Raphael Itzykson, Sylvain Thépot, Claire Fabre, François Dreyfus, Bruno Quesnel, Eric Wattel, Stephane de Botton, Sylvain Pilorge, Caroline Dartigeas, Aspasia Stamatoullas, Thomas Prebet, Mario Ojeda-Uribe, Eric Solary, Gandhi Damaj, Gerard Tertian, Chantal Himberlin, Rose-Marie Mbida, Lionel Adès, Claude Gardin and Pierre Feneaux. Response to azacytidine (AZA) in MDS or AML with del 5q : Current results of the French ATU program. Blood Nov 2008; 112: 2682. (ASH Annual Meeting Abstracts) (P) 26. Bruno Lioure, Cristian Recher, Patrice Chevallier, Arnaud Pigneux, Francis Witz, Norbert Vey, Nathalie Fegueux, Claude-Eric Bulabois, Sylvie Daliphard, Frabrice Larosa, Martine Escoffre-Barbe, Eric Jourdan, Olivier Tournilhac, Martine Delain, Denis Caillot, Mario Ojeda, Edouard Randriamalala, Roselyne Delepine, François Dreyfus, Norbert Ifrah. Absolute lymphocyte count at 1st remission is prognostic factor for disease free and overall survival for acute myeloid leukaemia under 60 : Analysis of AML1 GOELAMS Trial. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 2520. (P) 27. R Houot, S Le Gouill, C Mounier, K Bouabdallah, M Ojeda-Uribe, D Senecal, M Alexis, A Arekelian, M Gardembas, O Tournihlac, P Rodon, R Gressin. RIPAD+C regimen including Velcade in front line therapy for elderly patients with mantle cell lymphoma. A Phase II prospective study of the Goelams Group. Hematologie 2010;16:71 (Annual Meeting Société Française d’Hématologie, Paris, France, 2010) (Oral-P) 28. Remy Gressin, Roch Houot, Mario Ojeda-Uribe, Christiana Mounier, Krimo Bouabdallah, Magda Alexis Vigier, Delphine Senecal, Martine Gardembas, Olivier Tournihlac, Sophie Park, Philippe Rodon, Abderrazak El Yamani, Laurent Sutton, Bruno Lioure, David Assouline, Jean Luc Harousseau, Hervé Maisonneuve, Sylvie Caulet-Maugendre, Steven Le Gouill. Velcade/Adriblastine/dexamethasone/chroloraminophene (RIPAD+C) regimen in front line theraoy for elderly mantke cell lymphoma patients : A phase II prospective study of the GOELAMS group. Blood (ASH Annual Meeting Abstracts) 52th Meeting American Society of Hematology 2010, Orlando, U.S.A (P) 29. Mario Ojeda-Uribe, Celine Haby, Alain Gravet, Catherine Berg, Olivier Aujoulat, Eric Jeandidier, Caroline Lohmann, Bernard Drenou, and Benoît Lesquerbault. Results of a Prospective Non-Randomized Trial Comparing the Efficacy of Voriconazole (Vor) and Posaconazole (Pos) As Primary Prophylactic Agents of Invasive Fungal Infections (IFI) in Acute Leukemic Patients. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 1120 (P) 30. Mathilde Hunault, Thibault Legay, Françoise Huguet, Stéphane Leprêtre, Eric Deconinck, Mario Ojeda Uribe, Caroline Bonmati, Bruno Lioure, Catherine Himberlin, Patrice Chevallier, Philippe Rousselot, Oumedaly Reman, Marie-Laure Boulland, Véronique Lhéritier, Severine Lissandre, Pascal Turlure, Didier Bouscary, Laurence Sanhes, Ollivier Legrand, Isabelle Plantier, Frédérique Orsini Piocelle, David Liens, Yann Godfrin, Norbert Ifrah, and Herve Dombret. L-Asparaginase-Loaded Red Blood Cells Combined with Standard EWALL Chemotherapy in Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (Ph- ALL): First Results of the GRASPALL/GRAALL-SA2-2008 Study. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 2579. (P) 31. Jacques Delaunay, Christian Recher, Arnaud Pigneux, Francis Witz, Norbert Vey, Odile Blanchet, Pascale Lefebvre, Isabelle Luquet, Isabelle Guillerme, Christelle Volteau, Emmanuel Gyan, Bruno Lioure, Eric Jourdan, Didier Bouscary, Romain Guieze, Edouard Randriamalala, Mario E Ojeda Uribe, Francois Dreyfus, Catherine Lacombe, Marie-christine Béné, Jean-Yves Cahn, Jean-Luc Harousseau, and Norbert Ifrah. Addition of Gemtuzumab Ozogamycin to Chemotherapy Improves Event-Free Survival but Not Overall Survival of AML Patients with Intermediate Cytogenetics Not Eligible for Allogeneic Transplantation. Results of the GOELAMS AML 2006 IR Study. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 79. (Oral-P) 32. David Sibon, Ana Berceanu, David Ghez, Frantz Foissac, Leila Kammoun, Thorsten Braun, Denis Caillot, Mario Ojeda-Uribe, Romain Guieze, Céline Berthon, Laurence Sanhes, Bérengère Gruson, Didier Bouscary, Christian Recher, Laure Stalnikiewicz, Philippe Rousselot, Emmanuel Raffoux, Thomas Prebet, Bruno Salles, Stéphane de Botton, Ambroise Marcais, Felipe Suarez, and Olivier Hermine. Use of Clofarabine in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Adults: The French Experience. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 2623 (P) 33. I Harzallah, M Chemais, A Debliquis, V Rimelen, C Bidoire, N Pierrot, Y Arkam, M Ojeda, JC Eisenmann, B Drénou. Expression de ZAP 70 dans la leucémie lymphoïde chronique : stratégies cytométriques usuelles prises en défaut. Hématologie 2012, abstract 05-42 (Annual Meeting Societé Française d’Hématologie) (P) 34. D Sibon, A Berceanu, D Ghez, F Foissac, L Kammoun, T Braun, D Caillot, M Ojeda-Uribe, C Recher, P Rousselot, E Raffoux, O Hermine. Utilisation de la clofarabine dans le traitement des leucémies aiguës myéloïdes en rechute/ réfractaires de l’adulte : l’expérience française. Hématologie 2012, abstract 07-23 (Annual Meeting Societé Française d’Hématologie) (P) 35. Godfrin Y, Hunault M, Leguay T, Huguet F, Leprêtre S, Deconinck E, Ojeda-Uribe M, Bonmati C, Bories P, Himberlin C, Chevallier P,Rousselot P, Reman O, Boulland ML, Boucher E, Lissandre S, Turlure P, Bouscary D, Sanhes L, Legrand O, Plantier I, Orsini Piocelle F, Liens D, Ifrah N, Dombret H. Main results of GRASPALL/GRAALL-SA2-2008 Study: L-Asparaginase-Loaded red blood cells added to EWALL chemotherapy in older patients with Philadelphia Chromosome-negative Acute Lymphoblastic Leukemia. (EHA 2012 Annual Meeting, June 2012) (Oral-P) 4.0 OTHER MEETING PRESENTATIONS 4.1 ORAL COMMUNICATIONS 1. Pizarro O, Ojeda M. Human aglutinins against mice red blood cells and X chromosome. XXV Meeting of the Sociedad de Biologia de Chile. P. de Tralca, Chili 1981 2. Ojeda M, Miranda M, Jerez C, Mendez J, Mendoza J. Seric beta-N-acetil glucosaminidase in patients with instertitial lung fibrosis.II Congress of Internal Medicine, Hospital San Juan de Dios, Santiago du Chili, Chili 1982 3. Etcheverry R, Daiber A, Vacarezza R, Ojeda M, Duran N. Syndrome of the sea-blue histiocyte. Clinical and structural study of 6 patients. VI Chilean Congress of Hematology, Santiago du Chili, Chili 1986 4. Ojeda M, Minguell J, Walter T, Maldonado J. Ex-vivo manipulation of canine bone marrow. VI Chilean Congress of Hematology, Santiago du Chili, Chili 1986 5. Ojeda M. Frequency and characterization of spindle-shaped fibroblastoid CFC progenitors in bone marrow and peripheral blood. II International Symposium on Peripheral Blood Stem Cell Autografting, Mulhouse, France 1991 6. Ojeda M, Brunot A, Finat-Duclos F, Fleury J, Legros M. Failure to detect spindle-shaped fibroblastoid cells progenitors in PBPC collections. 9th Annual Meeting of the European Blood and Marrow Transplantation Group (EBMT), Garmisch-Partenkirchen, Allemagne 1993. 7. Ojeda M, Lioure B, Chenard MP, Tomasinelli F, Veillon F, Prevot G, Audhuy B. Successful ABMT in a leukemic patient with nodular pattern of liver veno-occlusive disease after conventional chemotherapy. 11th Meeting du Groupe de Travail des Oncologues du Rhin Supérieur (GTOR), Mulhouse, France 1994 8. Ph Henon, H Sovalat, M Becker, Y Arkam, M Ojeda, E Wunder, D Bourderont. Determination of the number of infused CD34+/38- cells for accurate prediction of both early and sustained multilineage hematopoietic engraftment. 4th Blood Cell Transplantation Meeting, Adelaide, South-Australia, 24-27 Mars,1996 9. Henon Ph, Sovalat H, Becker M, Arkam Y, Ojeda M, Bourderont D. Role of CD34+CD38- cells in posttransplant hematopoietic recovery. Eight International Symposium on Autologous Marrow and Blood Transplantation, Arlington, USA, 18-21 August, 1996. 10. Ph Henon Ph, H Sovalat, D Bourderont, Y Arkam Y, M Ojeda –Uribe. Role of CD34+ subsets for predicting recovery in autografts. 4th European Workshop on Stem Cell Methodology, Vienne, Autriche, 31 august – 4 september 1997. 11. Ph Henon Ph, H Sovalat, D Bourderont, Y Arkam Y, M Ojeda –Uribe. The decision for hematopoietic gowth factor administration after blood cell transplant should depend on the graft richness in CD34+CD38- cells. Fifth International Blood Cell Transplant Symposium, Omaha, Nebraska, USA, 5-8 octobre 1997. 12. Ph Henon Ph, H Sovalat, D Bourderont, Y Arkam Y, M Ojeda –Uribe. CD34+CD38- cell-enriched blood graft products might be the close future for autologous transplant. 10th Anniversary of the Hematology Institute of Shangai, Chine, 30 octobre – 5 novembre 1997. 13. Ojeda-Uribe M, Sovalat H, Bourderont D, Arkam Y, Henon Ph. Is the CD34+38- cell subset more resistant to cryopreservation than the CD34+38+ one ?. 6th Int. Symposium on PBSC Transplantations. Mulhouse, France 1999 14. Henon Ph, Bischoff N, Monassier JP, Ojeda M, Arkam Y, Sovalat H, Debecker A, Dallemand R, Le Bouar R. Mobilized and purified autologous CD34+ cell transplantation for myocardial regeneration.32th Annual Meeting International Society of Experimental Hematology, Paris, France, 2003 15. Henon Ph, Ojeda M, Arkam Y, Sovalat H, Bischoff N, Dallemant R, Monassier JP. Cardiomyoplastie cellulaire de cellules CD34+ sanguines autologues. 2ème Congrès de la Societé Française de Bioingénierie Cellulaire et Tissulaire, Paris, France, 2003 16. H Sovalat, M Ojeda, H Lewandowski, A Kapsa, Ph Henon. Expression of cell adhesion molecules on cord blood and bone marrow hematopoietic progenitors. First Annual Meeting of Stem Cell Therapeutics Excellence Centre and 8th Scientific Symposium of Experimental Cardiology Group of Polish Cardiological Society “Molecular Biology in Cardiology”. Cracovie, Pologne, 23-25 Octobre, 2003. 17. CD34+ cells intra-cardiac transplantation regenerates viability, perfusion and contractability of the ischemic zone following severe acute myocardial infarct (AMI). Ph. Henon, H. Sovalat, S. Pasquet-Vallejo, N.Bischoff, Y. Arkam, M. Ojeda-Uribe, JP.Monassier, International Symposium on Bioengineering and Regenerative Medicine, Mulhouse, France, 24-26 Septembre, 2007 4.2 POSTER COMMUNICATIONS 1. Ojeda M, Beuvon F, Tang RP, Pouillart P. Role of CSF-1 as a growth factor for breast cancer cells expressing the CSF-1 receptor (fms). Proceedings of the Cell to Cell Interaction Symposium, Bâle, Suisse,1990 2. Ojeda M, Beuvon F, Tang RP, Pouillart P. Role of CSF-1 and its receptor (fms) in the acquisition of an invasive phenotype by the breast cancer cells. XIIèmes Journées de la Société Française de Sénologie et de Pathologie Mammaire, Paris, France, 1990 3. Tang RP, Ojeda M, Beuvon F, Pouillart P, Scholl S. Macrophages markers in breast adenocarcinoma. III International Congress on Neo-adjuvant Chemotherapy, Paris, France, 1991 4. Ojeda M, Rapatel C, Brunot A, Legros M, Fleury J. P-gp expression in the lymphoid cell population of bone marrow and peripheral blood leukapheresis. 19th Annual Meeting of the European Blood and Marrow Transplantation Group (EBMT), Garmisch-Partenkirchen, Allemagne, 1993 5. Ojeda M, Brunot A, Fleury J, Bertheas MF, Legros M. In vitro pre-B cell proliferation from peripheral blood after hematopoietic stem cell mobilization with chemotherapy and rG-CSF. 19th Annual Meeting of the European Blood and Marrow Transplantation Group (EBMT), Garmisch-Partenkirchen, Allemagne, 1993 6. Ojeda M, Tournade A, Tajamadhy T, Lioure B, Stilhart B, Mors R, Audhuy B. A case of multiple myeloma presenting as plasmacytome of the base of the skull. International Conference INSERM “Multiple Myeloma, from biology to therapy, current concepts”. Mulhouse, France, 1994 7. Brunot-Ojeda A, Schneider Ch, Ojeda-Uribe M. Economic impact of delayed platelet reconstitution after autologous stem cell transplantation (ASCT). 6th International Symposium on PBSC Transplantations. Mulhouse, France, 1999 8. Sovalat H, Ojeda M, Racadot E, Henon Ph. G-CSF effect upon expression of surface adhesion molecules on CD34+ hematopoietic progenitors. 6th International Symposium on PBSC Transplantations. Mulhouse, France, 1999 9. M Ojeda Uribe, H. Sovalat, D Bourderont, P Henon. When cryopreserved hematopoietic stem cells (HSC) from patients with acute leukaemia show better post-thaw viability values than HSC from myeloma and Non Hogdkin’s lymphoma patients. World Congress on Biotechnology, Santiago du Chili, Chile, 2004 10. Ojeda Uribe M, Debry C, Schultz P, Kiefer MH ,Chain J, Chenard MP, Herbrecht R. Lessons from a case of orofacial zygomycosis and pulmonary aspergillosis in a leukemic patient treated by surgery and by an antifungal association including amphotericine B lipid formulations and Caspofungin. Congress Chilean Society of Internal Medicine, Viña del Mar, Chile, 2006 11. M. Ojeda Uribe, A Gravet, C Berg. D Bourderont. Comparative evaluation of voriconazole versus posaconazole versus no systemic agent for primary prophylaxis of invasive fungal infections during induction and consolidation courses of adult acute lymphoblastic and myeloblastic leukemic patients. XIX World Congress on Internal Medicine, Buenos Aires, Argentina, 2008 12. M. Ojeda-Uribe, B. Drénou, C. Caron, C. Coman Damian,G. Jung, A. Debliquis. Efficacité du Bortezomib après echec du Rituximab chez un patient presentant un Syndrome de Willebrand acquis associé à une MGUS. Annual Meeting Groupe Etude Hémostase et Thrombose (GEHT), Toulouse, France, 2009 13. Mario Ojeda-Uribe, Thierry Zame, Christian Meyer. Does Rituximab should be considered as an emergency treatment for relapsing idiopathic thrombotic thrombocytopenic purpura (TTP)? III Latin-American Congress on Autoimmunity, Buenos Aires, Argentina, 2010 5.0 EXPERIENCE AS INVESTIGATOR Principal investigator or co-investigator in more than one hundred clinical trials in France, Europe and at the International level. 6.0 SPOKEN AND WRITTEN LANGUAGES: Ø Spanish, French, English, Italian Date: 18 MAY, 2012 Signature

    Lire la suite

Ce site n'a pas pour vocation de remplacer une consultation médicale